Galaxy Therapeutics Inc. received CE mark approval under the European Medical Device Regulation for its SEAL embolization system, which is designed for the treatment of ruptured and unruptured wide-neck intracranial aneurysms. The company believes that the device can simplify aneurysm treatment while addressing a broad range of complex anatomies and offers physicians an alternative option for wide neck bifurcation aneurysms.